Pfizer India Q2 Net Profit Rises 19.4% to ₹189 Crore on Strong Sales and Cost Efficiency

Pfizer reported a strong financial performance for the September quarter (Q2 FY26), with net profit rising 19.4% year-on-year to ₹189 crore, compared to ₹158 crore in the same quarter last year. The growth was driven by higher sales across core therapeutic segments and improved cost management.

Revenue and Operational Performance

Pfizer’s revenue from operations increased 9.1% year-on-year to ₹642.3 crore, supported by steady demand in key therapeutic areas. The company’s EBITDA rose 21.5% to ₹229.8 crore, compared with ₹189.2 crore in the corresponding period last year.

EBITDA margins improved to 35.8%, up from 32.1%, aided by operational efficiencies and a focus on optimising input costs. Pfizer attributed the strong quarterly performance to consistent prescription growth, portfolio rationalisation, and disciplined expense control, which together enhanced profitability.

Exceptional Item from MIDC Asset Sale

During the financial year ended March 31, 2025, Pfizer completed the assignment and sale of its leased land and building assets to the Maharashtra Industrial Development Corporation (MIDC).

The company recorded a net gain of ₹172.81 crore from the transaction, which was classified as an exceptional item in its financial statements. The sale marked the completion of Pfizer’s planned divestment of select non-core real estate assets.

Dividend Declaration

At its Annual General Meeting (AGM) held on July 21, 2025, shareholders approved a total dividend of ₹165 per equity share, equivalent to 1,650% of the face value of ₹10.

• Final dividend: ₹35 per share
• Special dividend (75th anniversary): ₹100 per share
• Additional special dividend (MIDC asset sale gain): ₹30 per share

This payout reflects Pfizer’s strong financial position and commitment to delivering shareholder value while marking its 75th year of operations in India.

Financial Summary (Q2 FY26)

Read More: Cipla, Natco Pharma, and Other Firms Win Several Drug Supply Bids.

Conclusion

Pfizer India delivered a solid performance in the September quarter, supported by revenue growth, operational efficiency, and disciplined cost management. The improvement in margins and a strong dividend payout highlight the company’s stable financial health and steady business momentum in its key product categories.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.